MARKET

ATRS

ATRS

Antares Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.470
+0.090
+2.05%
Closed 16:01 07/28 EDT
OPEN
4.400
PREV CLOSE
4.380
HIGH
4.505
LOW
4.380
VOLUME
636.41K
TURNOVER
--
52 WEEK HIGH
5.07
52 WEEK LOW
2.550
MARKET CAP
754.53M
P/E (TTM)
12.28
1D
5D
1M
3M
1Y
5Y
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, bef...
GlobeNewswire · 7h ago
Antares To Start Testing ATRS-1902 With Injector Technology In Patients With Adrenal Crisis
Benzinga · 6d ago
BRIEF-Antares Pharma Announces FDA Acceptance Of IND Application For ATRS-1902
reuters.com · 6d ago
Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue
Antares Pharma, Inc. (NASDAQ: ATRS) ("the Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue. T...
GlobeNewswire · 6d ago
Antares Gets US FDA OK to Start Trial of ATRS-1902 in Acute Adrenal Insufficiency
MT Newswires · 6d ago
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
 
Benzinga · 07/16 14:15
Truist Securities Initiates Coverage On Antares Pharma with Buy Rating, Announces Price Target of $7
Truist Securities analyst Gregg Gilbert initiates coverage on Antares Pharma (NASDAQ:ATRS) with a Buy rating and announces Price Target of $7.
Benzinga · 07/16 10:44
Is Antares Pharma, Inc.'s (NASDAQ:ATRS) Stock's Recent Performance A Reflection Of Its Financial Health?
Antares Pharma's (NASDAQ:ATRS) stock up by 8.0% over the past three months. Since the market usually pay for a...
Simply Wall St. · 07/11 07:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRS. Analyze the recent business situations of Antares Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRS stock price target is 6.57 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 228
Institutional Holdings: 91.68M
% Owned: 54.31%
Shares Outstanding: 168.80M
TypeInstitutionsShares
Increased
56
13.44M
New
23
2.89M
Decreased
47
3.26M
Sold Out
25
3.50M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.00%
Healthcare Equipment & Supplies
+0.89%
Key Executives
Chairman/Independent Director
Leonard Jacob
President/Chief Executive Officer/Director
Robert Apple
Chief Financial Officer/Executive Vice President
Fred Powell
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Peter Graham
Executive Vice President
Peter Richardson
Independent Director
Thomas Garrity
Independent Director
Peter Greenleaf
Independent Director
Anton Gueth
Independent Director
Robert Roche
Independent Director
Karen Smith
No Data
About ATRS
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Webull offers kinds of Antares Pharma Inc stock information, including NASDAQ:ATRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRS stock methods without spending real money on the virtual paper trading platform.